Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 26863606 |
US |
56 | 2 |
Pruritus, Skin burning sensation, Injection site rash, Injection site pruritus, Dermatitis atopic, |
||||
DUPILUMAB, ROFLUMILAST, |
||||
| 602 | 26863624 |
CA |
67 | 2 |
Lymphoma, Depression, Dermatitis atopic, Discouragement, Wound, Condition aggravated, Skin lesion, Pruritus, Nervousness, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DESONIDE, DESONIDE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, PROGESTERONE, CANDESARTAN, AMLODIPINE, HYDROXYCHLOROQUINE SULFATE, CALCIUM, BUPROPION HYDROCHLORIDE, DESVENLAFAXINE SUCCINATE, NALTREXONE, PREDNISONE, |
||||
| 603 | 26863859 |
US |
79 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 604 | 26863912 |
US |
29 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 605 | 26864014 |
US |
21 | 2 |
Arthralgia, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 606 | 26864165 |
US |
50 | 1 |
Sleep disorder due to a general medical condition, Arthralgia, Gait disturbance, Dyshidrotic eczema, Eczema, Dermatitis atopic, Dry skin, Eye discharge, Skin exfoliation, Eye inflammation, Dry eye, |
||||
DUPILUMAB, |
||||
| 607 | 26864474 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 608 | 26864481 |
US |
19 | 1 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 609 | 26864487 |
US |
2 | |
Urticaria, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 610 | 26864490 |
US |
65 | 1 |
Eye disorder, Dermatitis atopic, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 611 | 26864492 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 612 | 26864540 |
US |
71 | 1 |
Dermatitis atopic, Device defective, |
||||
DUPILUMAB, |
||||
| 613 | 26864891 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 614 | 26864915 |
US |
55 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 615 | 26864948 |
US |
80 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 616 | 26864968 |
US |
59 | 1 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 617 | 26864991 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, FLUTICASONE PROPIONATE, MONTELUKAST SODIUM, |
||||
| 618 | 26865350 |
US |
1 | |
Dermatitis atopic, Superficial injury of eye, Therapeutic response shortened, |
||||
DUPILUMAB, ALBUTEROL SULFATE, LORATADINE, LORATADINE TABLET, CRISABOROLE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, IRON, |
||||
| 619 | 26865381 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 620 | 26865394 |
US |
2 | |
Dermatitis atopic, Rash, Discomfort, Oral herpes, |
||||
DUPILUMAB, CYCLOBENZAPRINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 621 | 26865395 |
US |
36 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 622 | 26865561 |
EU |
61 | 2 |
Hypertension, Feeling abnormal, Acne, Lacrimation increased, Eye pruritus, Nausea, Dermatitis atopic, Dyspnoea, Rash, Paraesthesia, |
||||
LEVODOPA, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 623 | 26865847 |
US |
1 | |
Dermatitis atopic, Rash, Rash erythematous, Inflammation, |
||||
DUPILUMAB, |
||||
| 624 | 26866226 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 625 | 26866232 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 626 | 26866235 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 627 | 26866405 |
GB |
1 | |
Skin toxicity, Dermatitis atopic, |
||||
LAZERTINIB, |
||||
| 628 | 26866774 |
US |
43 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 629 | 26867046 |
US |
1 | |
Dermatitis atopic, Dry skin, Skin fissures, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 630 | 26867286 |
US |
74 | 2 |
Blister, Rash macular, Pain of skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 631 | 26867292 |
US |
21 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 632 | 26867295 |
US |
46 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 633 | 26867441 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 634 | 26867509 |
US |
2 | |
Dermatitis atopic, Intentional product misuse, Therapeutic response unexpected, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 635 | 26867620 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 636 | 26867621 |
US |
2 | |
Stress, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 637 | 26867622 |
US |
5 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 638 | 26867651 |
US |
1 | |
Eye irritation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 639 | 26867652 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 640 | 26867747 |
US |
33 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 641 | 26867925 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 642 | 26857558 |
US |
57 | 2 |
Injection site reaction, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 643 | 26857744 |
US |
73 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL SULFATE, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FAMOTIDINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, MONTELUKAST SODIUM, |
||||
| 644 | 26857752 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 645 | 26858084 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 646 | 26858325 |
US |
2 | |
Asthma, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 647 | 26858326 |
US |
52 | 2 |
Injection site pruritus, Dermatitis atopic, Dry skin, Erythema, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 648 | 26858342 |
US |
2 | |
Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 649 | 26858407 |
EU |
35 | 1 |
Pulmonary infarction, Pulmonary embolism, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 650 | 26858609 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 651 | 26858631 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 652 | 26858654 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 653 | 26858779 |
US |
53 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, |
||||
| 654 | 26858844 |
US |
25 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, |
||||
| 655 | 26858991 |
US |
66 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 656 | 26859010 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 657 | 26859020 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 658 | 26859023 |
US |
70 | 2 |
Dry skin, Pruritus, Hyperhidrosis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 659 | 26859074 |
US |
47 | 2 |
Hypersensitivity, Dermatitis atopic, Asthma, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 660 | 26859169 |
US |
22 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 661 | 26859400 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 662 | 26859427 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 663 | 26859836 |
US |
22 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 664 | 26860053 |
US |
53 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, DUPILUMAB, |
||||
| 665 | 26860088 |
US |
57 | 2 |
Gallbladder disorder, Liver disorder, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 666 | 26860274 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 667 | 26860293 |
US |
3 | 2 |
Dermatitis atopic, Pruritus, Eczema, Rebound effect, Rash erythematous, Butterfly rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 668 | 26860306 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 669 | 26860601 |
US |
1 | |
Dermatitis atopic, Discomfort, Product dose omission in error, Rash, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 670 | 26860609 |
US |
77 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 671 | 26860611 |
US |
1 | |
Pruritus, Erythema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 672 | 26860619 |
US |
5 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 673 | 26860622 |
US |
24 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, DELGOCITINIB, CRISABOROLE, |
||||
| 674 | 26861142 |
CA |
||
Dermatitis exfoliative generalised, Oedema peripheral, Skin exfoliation, Dermatitis atopic, Erythema, Hot flush, |
||||
| 675 | 26861293 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 676 | 26861303 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 677 | 26861557 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 678 | 26861866 |
US |
21 | 2 |
Illness, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 679 | 26861871 |
US |
87 | 1 |
Rhinorrhoea, Nausea, Dermatitis atopic, Rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 680 | 26861875 |
US |
2 | |
Dermatitis atopic, Treatment noncompliance, |
||||
DUPILUMAB, |
||||
| 681 | 26861882 |
US |
2 | |
Dermatitis atopic, Drug effect less than expected, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 682 | 26862179 |
US |
18 | 2 |
Conjunctivitis, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 683 | 26862276 |
US |
17 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 684 | 26862312 |
US |
46 | 2 |
Dermatitis atopic, Erythema, Rash, |
||||
DUPILUMAB, |
||||
| 685 | 26862369 |
US |
2 | |
Rash macular, Rash pruritic, Skin tightness, Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 686 | 26862518 |
US |
1 | |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 687 | 26862531 |
US |
7 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 688 | 26852226 |
US |
47 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 689 | 26852377 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 690 | 26852382 |
US |
51 | 2 |
Rash, Dermatitis atopic, Dry skin, Pruritus, Skin weeping, |
||||
DUPILUMAB, |
||||
| 691 | 26852390 |
US |
18 | 1 |
Dysgeusia, Wisdom teeth removal, Dermatitis atopic, |
||||
DUPILUMAB, LORATADINE, LORATADINE ORAL, AMOXICILLIN, ATOMOXETINE HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE, |
||||
| 692 | 26852596 |
US |
56 | 1 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 693 | 26852605 |
US |
59 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 694 | 26852607 |
US |
33 | 2 |
Dermatitis, Bronchitis, Asthma, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, BENRALIZUMAB, |
||||
| 695 | 26852624 |
US |
59 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 696 | 26852844 |
US |
64 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 697 | 26853152 |
US |
6 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 698 | 26853173 |
US |
68 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 699 | 26853179 |
US |
9 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 700 | 26853196 |
US |
61 | 2 |
Dermatitis atopic, Neurodermatitis, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30